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positioning with accuracy ±0.1 mm. It is logical to assume 
that if we reduce thickness (1mm) of the measuring tip by 
the order of magnitude (to 0.1 mm) the accuracy as well to 
be reduced by the order of magnitude (i.e. ±0.01 mm). Since 
for human eye it is difficult to discern such small objects we 
found optical instruments to perform control of reliable 
positioning ionization chamber to 'calibration point'. As a 
close focus telescope we use Universal 8x Telescope with 8 
dioptres lens at the entrance window. CNMC WP-380 water 
tank and its positioning assembly were used for mounting 
holder of the radioactive source. In the new design of the 
holder we tried to minimize the amount of other than water 
surrounding material. For measuring length of the device 
itself we use the same concept of the reflection of the tip in 
the surface of caliper jaw (10x magnifying glasses is needed). 
To reduce uncertainty of the source inside mould probe (from 
±0.25 mm to ±0.1 mm) we used the method of 'curved 
catheter'. The special care was taken about levelness of 
removable mirror, which play a role of 'base plane', for all 
measurements of the distance. Final mechanical uncertainty 
for distance we estimate as ±0.12 mm, which correspond to 
the inaccuracy in dose: ±0.6 %. GammaMed Plus remote 
afterloader with source Ir-192 HDR (capsule diameter 0.9 
mm) was used. The 0.6 cc Farmer chamber type was placed 
into standard phantom holder. Varian BrachyVision V10(TG-
43) treatment planning system (TPS) was used for 
comparison. 
  
Figure: 1 - Farmer ionization chamber; 2 - Positioning device; 
3 – Removable mirror; 4 – Measuring tip of the device and its 
reflection in the mirror; 5 – Mould probe ø1.8x320 mm 
(GM11002290)  
 
Results: Farmer chamber calibration factor ND,w =5.352·107 
Gy/C. Beam quality factor for Ir-192 (380keV) kQ =0.992 was 
found by interpolation Decay factor is 1.001. Reading: 7.800 
nC/min. Correction kT,P =0.9941. Result for dose rate: 0.4123 
Gy/min. Source-to-chamber distance is 42.85 mm 
(summation of: 39.81 mm - positioning device length; (0.05-
0.025)mm – device correction; 3.41 mm - chamber radius; -
1.0 mm source-'base plane' distance; 0.6 mm - correction of 
chamber centre due to chamber dimensions). At the source-
chamber distance 42.85 mm the TPS gives dose rate 0.4123 
Gy/min (or difference with measurements 1.3%). Taking into 
account absolute calibration of the source activity correction 
(-1%) by well-chamber, final difference reduces to 0.3%. 
Conclusions: The measured dose rate at the distance ~ 4 cm 
shows an agreement with TPS within 1%. Proposed positioning 
device demonstrates a good repositioning ability and absolute 
accuracy in settings source-to-chamber distance for 
brachytherapy phantom and can be considered as a primary 
standard (gauge) for this type of settings/calibrations.  
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Purpose/Objective: Non Melanoma skin cancers account for 1 
in 5 new malignancies in the UK [NCIN 2013]. High dose rate 
brachytherapy has been identified as a treatment modality 
for skin cancers for some indications [Guix 2000, Köhler-
Brock 1999, Lovett 1990, Sabbas 2004]. Conventional 
treatment planning systems (TPS) for brachytherapy utilise 
the TG-43 algorithm [Rivard 2004] for dose calculation. TG-43 
calculates dose using single source dose superposition in an 
infinite water medium [Rivard 2009]. For most brachytherapy 
applications (e.g.pelvic targets such as gynaecological and 
prostate malignancies) this algorithm is acceptable as the 
targets are typically located deep within tissue, within a 
relatively full scatter environment. However, for surface 
targets the formalism of a full scatter environment no longer 
holds [Raina 2005]. Dose distributions calculated in the 
treatment planning system for such sites will thus be 
inaccurate, and may result in a superficial underdosage to 
the target. The aim of this project is to quantify the 
discrepancy between the TPS and the actual treatment 
delivery due to incomplete scatter environments. 
Materials and Methods: The Freiburg Flap Applicator 
(Nucletron) was proposed as a modality for the treatment of 
superficial lesions with HDR Brachytherapy. Treatment 
Surface Areas (TSAs) of different sizes were planned using a 
CT dataset of the Freiburg flap and the Oncentra Brachy 
version 4.3 (Nucletron Elekta) TPS using an Ir-192 radiation 
source. The Freiburg flap and OncoSmart catheter system 
were set up on a PTW OCTAVIUS 729 ion chamber array with 
11.6 cm of solid water above and 10 cm below the apparatus 
to simulate complete scatter environment. The TSAs were 
delivered using the Flexitron remote afterloading device and 
the response was measured using Verisoft software. The 
amount of solid water above the flap was incrementally 
reduced to observe the effect of decreasing scatter 
environment. The underdosage for each TSA size was 
examined and compared with the dose distribution as 
calculated by the TPS. 
Results: As solid water is removed the response sequentially 
decreases – i.e. an underdosage is observed (see graph). The 
trend below is observed for all TSAs; as the scatter 
environment is reduced the response decreases. As solid 
water is removed the response sequentially decreases – i.e. 
an underdosage is observed (see graph). The trend below is 
observed for all TSAs; as the scatter environment is reduced 
the response decreases. 
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The magnitude of underdosage depends on the TSA size (see 
table below). The maximum underdosage (0 cm of solid 
water above flap) generally increases with increasing TSA 
size. However the sensitivity of the TSA to the initial 
reduction of scatter is greatest for the smallest TSA.  
 
 
 
Conclusions: Analysis of the results of this project is still 
ongoing. Considering AAPM recommends a dose calculation 
accuracy of ±2% and a dose delivery accuracy of 5-10% [Nath 
1997] in brachytherapy the underdosage observed is not 
trivial. It is suggested that the underdosage could be 
accounted for during the treatment planning process either 
by increasing the surface dose or by the addition of bolus.  
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Purpose/Objective: Since the past years, the evolution of 
brachytherapy techniques was unique. The main advances 
arise from many features, such as: new dose delivering 
techniques, accuracy in the absorbed dose calculations, 
optimized accessories for implants and patient quality 
assurance, and development of new radioactive sources. The 
Energetic and Nuclear Research Institute (IPEN-CNEN/SP), 
with the main radiotherapy centers in Brazil, created a new 
LDR 192Ir to be used for ocular, prostate and cerebral tumors 
in the low dose rate (LDR) range. The new 192Ir LDR source 
has a cylindrical geometry (3.0 mm and 4.5 mm for outer 
diameter and length, respectively), suitable for accessories 
and holders existent in the market. Since the dosimetric 
characteristics are fundamental for patient dose planning 
accuracy. 
This work evaluate the dosimetric parameters of a new LDR 
brachytherapy 192Ir source using Monte Carlo simulations. 
Materials and Methods: The dosimetric functions were 
obtained using the PENELOPE/penEasy 2008 Monte Carlo 
source code, using the track-length estimator due to the low 
energy of the 192Ir photons. All the dosimetric parameters 
used in this work were based in the American Association 
Physics in Medicine (AAPM) Task Group-43 (TG43). To 
separated simulations runs, with the source in air and liquid 
water phantom, were performed to calculate the air-kerma 
strength (Sk) and water-based dosimetric factors. 
Comparisons of the new 192Ir LDR source dosimetric 
parameters were also made with similar source in the 
market. Uncertainty analysis was computed to estimate the 
statistical variations of the simulated dosimetric data.  
Results: The simulations results provide analogous values 
with LDR brachytherapy sources, for the same energy range. 
The constant dose-rate (L) was 1.11± 0.01 cGy.(hU)-1, 0.5% 
different from a 192Ir LDR source (Best Industries, VA – USA) 
available in the market. Anisotropy functions for the new 192Ir 
LDR sources are slightly steep in few millimeters around the 
source tips, this effect is expected because the encapsulation 
is thicker in these regions than in the wall. Radial dose 
functions were higher around 4.0 cm from the center of 
source (transversal axis), this property shows the possibility 
to use this LDR source for deeper tumors, since the similar 
sources has the maximum radial dose function around 3.0 cm. 
Conclusions: The dosimetric parameters for new 192Ir LDR 
brachytherapy source were calculated using AAPM TG-43. Our 
results suggest that this source has dosimetric characteristics 
comparable with similar LDR commercial sources.  
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